Clinical Investigator Receives Warning Letter Over Subject Dosing

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Clinical Investigator Receives Warning Letter Over Subject Dosing

J.W. Schomisch

September 5, 2024 at 03:18 PM EST

A clinical investigator in Atlanta received an Aug. 20 Warning Letter for allegedly failing to ensure a clinical trial was conducted according to the investigational plan (21 C.F.R. §312.60). The Warning Letter to Dr. Julio Flamini with the Research Center of Atlanta was the result of a Feb. 28-March 11 inspection conducted as a part of the FDA’s Bioresearch Monitoring Progra... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Clinical Investigator Receives Warning Letter Over Subject Dosing

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT